PE20060860A1 - Vacuna basada en epitopes neutralizantes - Google Patents

Vacuna basada en epitopes neutralizantes

Info

Publication number
PE20060860A1
PE20060860A1 PE2006000029A PE2006000029A PE20060860A1 PE 20060860 A1 PE20060860 A1 PE 20060860A1 PE 2006000029 A PE2006000029 A PE 2006000029A PE 2006000029 A PE2006000029 A PE 2006000029A PE 20060860 A1 PE20060860 A1 PE 20060860A1
Authority
PE
Peru
Prior art keywords
protein
plant virus
gdf8
epitops
neutralizing
Prior art date
Application number
PE2006000029A
Other languages
English (en)
Inventor
David E Junker
Mark D Cochran
Kenneth E Palmer
Gregory P Pogue
Mark L Smith
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of PE20060860A1 publication Critical patent/PE20060860A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

REFERIDA A UNA PROTEINA DE FUSION QUE COMPRENDE: a) UN DOMINIO DEL PEPTIDO GDF8 O UN FRAGMENTO ANTIGENICO DEL DOMINIO DEL PEPTIDO GDF8, DONDE EL DOMINIO DEL PEPTIDO GDF8 COMPRENDE LOS RESIDUOS DE AMINOACIDOS 327 A 346 DE LA SEC ID NO:1; Y b) UNA PROTEINA DE ENVOLTURA DE UN VIRUS DE PLANTA, O UN FRAGMENTO DE UNA PROTEINA DE ENVOLTURA DE UN VIRUS DE PLANTA. LA PROTEINA DE ENVOLTURA DEL VIRUS DE PLANTA ES UNA PROTEINADE ENVOLTURA DE TOBAMOVIRUS TAL COMO VIRUS DEL MOSAICO DEL TABACO, CEPA U1 O U5. TAMBIEN SE PROVEEN VECTORES DE VIRUS DE PLANTAS QUE EXPRESAN LA PROTEINA DE FUSION. DICHAS PROTEINAS DE FUSION SON UTILES COMO INMUNOGENOS PARA LOGRAR RESPUESTAS INMUNES ANTI-GDF8 EN ANIMALES
PE2006000029A 2004-12-30 2006-01-03 Vacuna basada en epitopes neutralizantes PE20060860A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64040804P 2004-12-30 2004-12-30
US66569005P 2005-03-28 2005-03-28

Publications (1)

Publication Number Publication Date
PE20060860A1 true PE20060860A1 (es) 2006-09-04

Family

ID=36374780

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000029A PE20060860A1 (es) 2004-12-30 2006-01-03 Vacuna basada en epitopes neutralizantes

Country Status (11)

Country Link
US (2) US7432079B2 (es)
EP (1) EP1831372A2 (es)
JP (2) JP2008526201A (es)
AR (1) AR051853A1 (es)
AU (1) AU2005323087A1 (es)
CA (1) CA2594276A1 (es)
MX (1) MX2007008132A (es)
MY (1) MY144766A (es)
PE (1) PE20060860A1 (es)
TW (1) TW200634156A (es)
WO (1) WO2006073827A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0418317A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd vacina de aumento de crescimento à base de epitopo de neutralização
EP1831372A2 (en) * 2004-12-30 2007-09-12 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
WO2013028330A2 (en) * 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
JP6284248B1 (ja) * 2016-11-22 2018-02-28 セイコーインスツル株式会社 電気化学セル及び電気化学セルの製造方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1192510A (en) 1981-05-27 1985-08-27 Lawrence E. Pelcher Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
CA2014033C (en) 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5422110A (en) 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
AU2699192A (en) 1991-10-16 1993-05-21 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
DE69432815T2 (de) 1993-03-19 2003-12-11 Univ Johns Hopkins Med Wachstumsfaktor-8
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
BR9808878A (pt) 1997-02-05 2000-07-11 Biostar Inc Imunização contra moléculas endógenas
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6344597B1 (en) 1998-01-16 2002-02-05 Large Scale Biology Corporation Interspecific nicotiana hybrids and their progeny
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) * 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US6037456A (en) 1998-03-10 2000-03-14 Biosource Technologies, Inc. Process for isolating and purifying viruses, soluble proteins and peptides from plant sources
JP4544742B2 (ja) 1998-05-06 2010-09-15 メタモーフイクス・インコーポレーテツド Ｇｄｆ−８の阻害による糖尿病の処置法
AU781020B2 (en) 1999-05-04 2005-04-28 Kentucky Bioprocessing, Llc Viral expression vectors
US6284882B1 (en) 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
AU4889100A (en) 1999-07-30 2001-02-01 Pfizer Products Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
JP3341238B2 (ja) * 1999-09-14 2002-11-05 株式会社アクーヴ・ラボ 振動を人体に感じさせる方法及びその装置
AU8024100A (en) * 1999-10-13 2001-04-23 Roswell Park Memorial Institute Induction of a strong immune response to a self-tumor associated antigen
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
CA2497798A1 (en) * 2002-09-03 2004-04-22 Large Scale Biology Corporation Production of peptides in plants as viral coat protein fusions
AU2003285280A1 (en) 2002-12-11 2004-06-30 Pharmexa A/S Targeting single epitopes
KR20130036378A (ko) 2002-12-20 2013-04-11 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
BRPI0418317A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd vacina de aumento de crescimento à base de epitopo de neutralização
US20060281075A1 (en) * 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
EP1831372A2 (en) * 2004-12-30 2007-09-12 Schering-Plough Ltd. Neutralizing epitope-based growth enhancing vaccine

Also Published As

Publication number Publication date
AU2005323087A1 (en) 2006-07-13
AR051853A1 (es) 2007-02-14
CA2594276A1 (en) 2006-07-13
JP2011024590A (ja) 2011-02-10
US20090208522A1 (en) 2009-08-20
WO2006073827A3 (en) 2006-12-21
MX2007008132A (es) 2007-07-20
WO2006073827A2 (en) 2006-07-13
TW200634156A (en) 2006-10-01
MY144766A (en) 2011-10-31
EP1831372A2 (en) 2007-09-12
JP2008526201A (ja) 2008-07-24
US20060159696A1 (en) 2006-07-20
US7432079B2 (en) 2008-10-07

Similar Documents

Publication Publication Date Title
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
PE20142330A1 (es) Vacuna de peptido ch3 de ige
ECSP066683A (es) Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
PE20060860A1 (es) Vacuna basada en epitopes neutralizantes
CO6210756A2 (es) La proteina linfopoyetina estromal timica canina y usos de la misma
ATE426412T1 (de) Adjuvante influenza-vakzine
EA200601671A1 (ru) Идентификация собственных и чужеродных антигенов, вовлечённых в аутоиммунные заболевания
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
CY1114243T1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
DK1968632T3 (da) Forbedret influenzavaccine
NO20063026L (no) Antistoffer
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
AR020102A1 (es) Compuesto para la prevencion y/o tratamiento de la alergia; composicion farmaceutica, composicion cosmetica, composicion en forma de bebida, alimento y/oalimento para animales domesticos que lo comprende y uso de dicho compuesto o dicha composicion farmaceutica para la fabricacion de un alimento
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DE60228971D1 (de) Peptide aus dem g-protein des respiratorischen synzytialvirus und deren verwendung in einem impfstoff
CY1112654T1 (el) Διαμορφομερη βακτηριακων προσκολλητινων
ECSP10010327A (es) Péptidos del fviii y su uso para hemofílicos tolerantes
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)

Legal Events

Date Code Title Description
FC Refusal